Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Levosalbutamol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 10/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Albuterol SCHEMBL2489838 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL10025126 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| (S)-Albuterol SCHEMBL5881204 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL121596 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL122805 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29361075 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| (S)-Albuterol SCHEMBL29496690 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL4913 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Albuterol SCHEMBL28434340 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1CYP1A2CYP2D6TSHR | |
| Levosalbutamol SCHEMBL29620266 | 0.98 | TDP1 (1.00) | ADRB2ADRB1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 29790 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6423298-B1 | — | — | None | — | — | US | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-122071418-A | Preparation method of salbutamol sulfate, salbutamol sulfate injection and preparation method of salbutamol sulfate injection | 海南皇隆制药股份有限公司 | 2026-05-22 | — | — | CN | claimed |
| US-20260139860-A1 | PRODUCTS OF MANUFACTURE FOR THE TREATMENT, PREVENTION AND AMELIORATION OF MICROBIAL INFECTIONS | CENTRE FOR DIGESTIVE DISEASES (AU) | 2026-05-21 | — | — | US | claimed |
| EP-4743371-A1 | DEVICE FOR DISPENSING A FLUID PRODUCT | APTAR France SAS (FR) | 2026-05-20 | — | — | EP | claimed |
| WO-2026099512-A1 | MEDICAMENT DISPENSER DEVICE | PORTAL MEDICAL LIMITED (GB) | 2026-05-15 | — | — | WO | claimed |
| EP-4739600-A1 | DEVICE FOR DISPENSING A FLUID PRODUCT | APTAR France SAS (FR) | 2026-05-13 | — | — | EP | claimed |
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| US-12617809-B2 | Cardioprotective lipid and method of use | SIGNPATH PHARMA, INC. (US) | 2026-05-05 | — | — | US | claimed |
| US-12616803-B2 | Apparatus for dispensing inhalant medicament | METOPI PHARMACEUTICALS, INC. (US) | 2026-05-05 | — | — | US | claimed |
| WO-1992001446-A1 | SUSTAINED-RELEASE FORMULATIONS | APS RESEARCH LIMITED (GB) | 1992-02-06 | — | — | WO | claimed |
| CN-1057960-A | DELAY GALENIC PARENTERAL FORM FOR INJECTION | APLICACIONES FARMACEUTICAS (MX) | 1992-01-22 | — | — | CN | claimed |
| US-5080903-A | GALENICAL FORMS OF BETA-2-MIMETICS FOR ADMINISTRATION PERLINGUALLY AND SUBLINGUALLY | SOCIETE CIVILE DITE: "MEDIBREVEX" (FR) | 1992-01-14 | — | — | US | claimed |
| WO-1991019485-A1 | INJECTABLE SLOW-RELEASE GALENICAL | APLICACIONES FARMACEUTICAS, S.A. DE C.V. (MX) | 1991-12-26 | — | — | WO | claimed |
| EP-0223671-B1 | MEDICAMENT WITH A SYNERGISTIC ANTI-INFLAMMATORY EFFECT ON THE BASIS OF A CORTICOSTEROID AND A BETA-AGONIST | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1991-11-27 | — | — | EP | claimed |
| EP-0370632-A1 | Pharmaceutical solution containing salbutamol and cromoglycic acid | FISONS plc (GB) | 1990-05-30 | — | — | EP | claimed |
| US-4918057-A | Veterinary preparations | GLAXO GROUP LIMITED (GB) | 1990-04-17 | — | — | US | claimed |
| US-4871545-A | Pharmaceutical combination of nifedipine and salbutamol | EURO-CELTIQUE S.A. (LU) | 1989-10-03 | — | — | US | claimed |
| EP-0272393-A2 | Pharmaceutical combination | Euro-Celtique S.A. (LU) | 1988-06-29 | — | — | EP | claimed |
| EP-0223671-A1 | Medicament with a synergistic anti-inflammatory effect on the basis of a corticosteroid and a beta-agonist | CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES GALDERMA - CIRD GALDERMA (FR) | 1987-05-27 | — | — | EP | claimed |